Article Information
History
- June 7, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Melissa J. Harnois1,2,
- Maria Dennis1,
- Dagmar Stöhr3,
- Sarah M. Valencia1,
- Nicole Rodgers1,4,
- Eleanor C. Semmes1,5,
- Helen S. Webster1,
- Jennifer A. Jenks1,5,
- Richard Barfield6,7,
- Justin Pollara1,4,
- Cliburn Chan6,7,
- Christian Sinzger3,* and
- Sallie R. Permar1,8,*,†
- 1Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
- 2Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA
- 3Institute for Virology, Ulm University Medical Center, Ulm, Baden-Württemberg, Germany
- 4Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA
- 5Medical Scientist Training Program, Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA
- 6Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC 27710, USA
- 7Center for Human Systems Immunology, Duke University Medical Center, Durham, NC 27710, USA
- 8Department of Pediatrics, Weill Cornell Medicine, New York, NY 10065, USA
- ↵†Corresponding Author Contact Information
Corresponding Author: Sallie R. Permar, Phone: +1 212 746 4111, Email: sap4017{at}med.cornell.edu
Posted June 07, 2022.
Elite neutralizers of human cytomegalovirus are characterized by high magnitude plasma IgG responses against multiple glycoprotein complexes
